Literature DB >> 16000430

Susceptibility of Neisseria meningitidis to 16 antimicrobial agents and characterization of resistance mechanisms affecting some agents.

James H Jorgensen1, Sharon A Crawford, Kristin R Fiebelkorn.   

Abstract

Neisseria meningitidis represents a pathogen of great public health importance in both developed and developing countries. Resistance to some antimicrobial agents used either for therapy of invasive infections or for prophylaxis of case contacts has long been recognized, although specific guidelines for susceptibility testing have not been fully developed. We have examined the susceptibilities of a collection of 442 meningococcal clinical isolates from 15 countries to 16 antimicrobial agents. These included isolates recovered between 1917 and 2004, with representatives of all major serogroups. All isolates were tested by the Clinical and Laboratory Standards Institute (formerly NCCLS) broth microdilution method using Mueller-Hinton lysed horse blood broth, while a subset of 102 isolates was tested by agar dilution using Mueller-Hinton sheep blood agar. Most isolates provided adequate growth for MIC determinations by both broth and agar methods. Growth in broth was enhanced by CO(2) incubation and was required for two strains (1.7%). MICs of the study drugs compared favorably between the broth and agar methods (79 to 100% essential agreement), and MICs also generally agreed closely (92 to 100% essential agreement, excluding azithromycin) between broth tests incubated in the two different atmospheres. Elevated penicillin and ampicillin MICs (> or =0.12 microg/ml and > or =0.25 microg/ml, respectively) occurred in 14.3% and 8.6% of strains and were associated with polymorphisms of the penA gene encoding a modified penicillin-binding protein 2. None of the 442 isolates produced beta-lactamase. Elevated tetracycline and doxycycline (but not minocycline) MICs were associated with efflux-mediated resistance encoded by tet(B) in 13 strains. Resistance to sulfisoxazole in 21.7% of strains and to trimethoprim-sulfamethoxazole in 21.0% resulted from polymorphisms of folP encoding a modified dihydropteroate synthetase. Seven strains were resistant to rifampin due to mutations in the rpoB gene, and two strains were resistant to chloramphenicol due to production of chloramphenicol acetyltransferase mediated by catP. Two strains had reduced quinolone susceptibility due to mutations of gyrA. The determination of the susceptibilities of a large group of meningococcal strains (including strains with characterized resistance mechanisms) to 16 antimicrobial agents has served as the essential first step in defining susceptibility testing breakpoints specific for this organism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16000430      PMCID: PMC1169190          DOI: 10.1128/JCM.43.7.3162-3171.2005

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  32 in total

1.  Polymorphism of Neisseria meningitidis penA gene associated with reduced susceptibility to penicillin.

Authors:  A Antignac; P Kriz; G Tzanakaki; J M Alonso; M K Taha
Journal:  J Antimicrob Chemother       Date:  2001-03       Impact factor: 5.790

2.  Nonculture prediction of Neisseria meningitidis susceptibility to penicillin.

Authors:  A Antignac; J M Alonso; M K Taha
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

3.  Invasive meningococci with reduced susceptibility to penicillin in Portugal.

Authors:  Eugénia Ferreira; Manuela Caniça
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

Review 4.  Meningococcal disease.

Authors:  N E Rosenstein; B A Perkins; D S Stephens; T Popovic; J M Hughes
Journal:  N Engl J Med       Date:  2001-05-03       Impact factor: 91.245

5.  International clone of Neisseria meningitidis serogroup A with tetracycline resistance due to tet(B).

Authors:  Sharon A Crawford; Kristin R Fiebelkorn; Jan E Patterson; James H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

6.  Rifampicin-resistant meningococci causing invasive disease: detection of point mutations in the rpoB gene and molecular characterization of the strains.

Authors:  P Stefanelli; C Fazio; G La Rosa; C Marianelli; M Muscillo; P Mastrantonio
Journal:  J Antimicrob Chemother       Date:  2001-02       Impact factor: 5.790

Review 7.  Update on meningococcal disease with emphasis on pathogenesis and clinical management.

Authors:  M van Deuren; P Brandtzaeg; J W van der Meer
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

8.  Neisseria meningitidis with decreased susceptibility to penicillin: report from the SENTRY antimicrobial surveillance program, North America, 1998-99.

Authors:  S S Richter; K A Gordon; P R Rhomberg; M A Pfaller; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2001 Sep-Oct       Impact factor: 2.803

9.  Surveillance of antibiotic resistance in invasive isolates of Neisseria meningitidis in Australia 1994-1999.

Authors:  J W Tapsall; T Shultz; E Limnios; R Munro; J Mercer; R Porritt; J Griffith; G Hogg; G Lum; A Lawrence; D Hansman; P Collignon; P Southwell; K Ott; M Gardam; C J Richardson; J Bates; D Murphy; H Smith
Journal:  Pathology       Date:  2001-08       Impact factor: 5.306

10.  Neisseria meningitidis: evolution of penicillin resistance and phenotype in a children's hospital in Barcelona, Spain.

Authors:  C Latorre; A Gené; T Juncosa; C Muñoz; A González-Cuevas
Journal:  Acta Paediatr       Date:  2000-06       Impact factor: 2.299

View more
  23 in total

1.  Surveillance of antimicrobial resistance in Neisseria meningitidis from patients in the Cincinnati tristate region (Ohio, Kentucky, and Indiana).

Authors:  Joel E Mortensen; Mary Jo Gerrety; Larry D Gray
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

2.  Combined real-time PCR and pyrosequencing strategy for objective, sensitive, specific, and high-throughput identification of reduced susceptibility to penicillins in Neisseria meningitidis.

Authors:  Sara Thulin; Per Olcén; Hans Fredlund; Magnus Unemo
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

3.  Role of HrpA in biofilm formation of Neisseria meningitidis and regulation of the hrpBAS transcripts.

Authors:  R Brock Neil; Michael A Apicella
Journal:  Infect Immun       Date:  2009-03-16       Impact factor: 3.441

4.  Epidemiology of invasive meningococcal disease with decreased susceptibility to penicillin in Ontario, Canada, 2000 to 2006.

Authors:  Elizabeth M Brown; David N Fisman; Steven J Drews; Sharon Dolman; Prasad Rawte; Shirley Brown; Frances Jamieson
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

Review 5.  Efflux-mediated drug resistance in bacteria: an update.

Authors:  Xian-Zhi Li; Hiroshi Nikaido
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

Review 6.  Invasive meningococcal disease in the 21st century—an update for the clinician.

Authors:  Rachel Dwilow; Sergio Fanella
Journal:  Curr Neurol Neurosci Rep       Date:  2015-03       Impact factor: 5.081

7.  Phasevarions mediate epigenetic regulation of antimicrobial susceptibility in Neisseria meningitidis.

Authors:  Freda E-C Jen; Kate L Seib; Michael P Jennings
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

8.  Antibiotic susceptibility and characteristics of Neisseria meningitidis isolates from the African meningitis belt, 2000 to 2006: phenotypic and genotypic perspectives.

Authors:  Sara Thulin Hedberg; Hans Fredlund; Pierre Nicolas; Dominique A Caugant; Per Olcén; Magnus Unemo
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

9.  Management of a rifampicin-resistant meningococcal infection in a teenager.

Authors:  D Delaune; D Andriamanantena; A Mérens; E Viant; O Aoun; F Ceppa; M-K Taha; C Rapp
Journal:  Infection       Date:  2013-02-14       Impact factor: 3.553

10.  Meningococcal disease and climate.

Authors:  Helena Palmgren
Journal:  Glob Health Action       Date:  2009-11-11       Impact factor: 2.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.